Latest Breaking News On - Biocon biologicspetitionedregeneron - Page 1 : comparemela.com

EYLEA® (aflibercept) IPR and BPCIA Litigation Updates | Venable LLP

There has been a flurry of activity relating to proposed EYLEA® (aflibercept) biosimilars in November, starting with a BPCIA litigation against Celltrion’s proposed biosimilar CT-P42.